Broderick Brian C Sells 6,600 Shares of Moderna, Inc. (NASDAQ:MRNA)

Broderick Brian C reduced its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 30.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 15,000 shares of the company’s stock after selling 6,600 shares during the quarter. Broderick Brian C’s holdings in Moderna were worth $1,002,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in MRNA. Empowered Funds LLC boosted its position in shares of Moderna by 26.8% during the 1st quarter. Empowered Funds LLC now owns 4,276 shares of the company’s stock valued at $456,000 after acquiring an additional 904 shares during the last quarter. Sei Investments Co. lifted its holdings in Moderna by 16.4% during the first quarter. Sei Investments Co. now owns 84,910 shares of the company’s stock valued at $9,048,000 after purchasing an additional 11,977 shares in the last quarter. US Bancorp DE grew its position in shares of Moderna by 19.5% during the first quarter. US Bancorp DE now owns 23,107 shares of the company’s stock valued at $2,462,000 after purchasing an additional 3,771 shares in the last quarter. Avantax Advisory Services Inc. raised its stake in shares of Moderna by 53.3% in the first quarter. Avantax Advisory Services Inc. now owns 5,035 shares of the company’s stock valued at $537,000 after acquiring an additional 1,750 shares during the period. Finally, Bleakley Financial Group LLC lifted its holdings in shares of Moderna by 10.8% in the 1st quarter. Bleakley Financial Group LLC now owns 3,711 shares of the company’s stock worth $395,000 after buying an additional 362 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insider Buying and Selling at Moderna

In other news, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the transaction, the chief financial officer now directly owns 9,505 shares in the company, valued at approximately $571,440.60. This trade represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 2,930 shares of company stock worth $217,170 over the last ninety days. 15.70% of the stock is currently owned by corporate insiders.

Moderna Stock Down 5.6 %

Shares of NASDAQ:MRNA opened at $39.77 on Friday. The firm’s 50 day moving average price is $59.96 and its 200 day moving average price is $97.80. Moderna, Inc. has a fifty-two week low of $38.76 and a fifty-two week high of $170.47. The stock has a market cap of $15.30 billion, a price-to-earnings ratio of -6.83 and a beta of 1.69. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The firm had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. During the same period last year, the company earned ($1.39) earnings per share. The firm’s revenue for the quarter was up 3.8% on a year-over-year basis. As a group, equities research analysts predict that Moderna, Inc. will post -9.43 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Jefferies Financial Group cut their price target on Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a research report on Tuesday, October 15th. HSBC upgraded shares of Moderna from a “reduce” rating to a “hold” rating and set a $82.00 target price for the company in a research note on Wednesday, August 28th. The Goldman Sachs Group cut their price target on shares of Moderna from $178.00 to $139.00 and set a “buy” rating for the company in a report on Monday, September 16th. Deutsche Bank Aktiengesellschaft upgraded shares of Moderna from a “sell” rating to a “hold” rating and lowered their price target for the company from $85.00 to $80.00 in a report on Wednesday, August 7th. Finally, Barclays decreased their price objective on Moderna from $125.00 to $111.00 and set an “overweight” rating on the stock in a report on Friday, November 8th. Three investment analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $90.22.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.